14 results about "Sonic hedgehog" patented technology

The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.

The present invention aims to provide a method for efficiently producing a cell mass containing pituitary tissue from pluripotent stem cells. A method for producing a cell mass containing pituitary tissue, including the following steps (1) and (2):(1) a first step of suspension-culturing pluripotent stem cells to form a cell aggregate in the presence of a Wnt signal transduction pathway inhibiting substance,(2) a second step of suspension-culturing the aggregate obtained in the first step in the presence of a BMP signal transduction pathway activating substance and a Sonic hedgehog signal transduction pathway activating substance, thereby obtaining a cell mass comprising pituitary tissue.

The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3):(1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGFβ family signal transduction pathway inhibiting substance and / or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state,(2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and(3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.

Provided are: a method for producing a spinal cord organoid from a pluripotent stem cell in vitro, the method comprising (1) a step for culturing a human pluripotent stem cell in a culture medium that contains a ROCK inhibitor and a Wnt signal activator but does not substantially contain a TGFβ inhibitor or a BMP signal inhibitor, (2) a step for further culturing the cell obtained in step (1) in a culture medium that contains a retinoic acid receptor agonist and a hedgehog signal activator, and (3) a step for further culturing the cell obtained in step (2) in a culture medium that does not substantially contain a TGFβ inhibitor, a BMP signal inhibitor, a retinoic acid receptor agonist, or a sonic hedgehog stimulator to obtain a spinal cord organoid; and a spinal cord organoid obtained by the method. The spinal cord organoid according to the present application comprises at least a portion of the dorsal side of the spinal cord and a ventral region of the spinal cord.

The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.

The present invention provides a method for preparing retinal pigment epithelial cells, comprising (1) a first step of subjecting pluripotent stem cells to suspension culture in a serum-free medium to form aggregates of the pluripotent stem cells, (2) a second step of subjecting the aggregates of the pluripotent stem cells to suspension culture in a serum-free medium to form aggregates of the pluripotent stem cells. (1) a third step in which the aggregate formed in step (1) is subjected to suspension culture in a serum-free medium or a serum-containing medium, each of which does not contain a substance acting on the Sonic hedgehog signal transduction pathway and contains a substance acting on the BMP signal transduction pathway, to obtain an aggregate containing retinal progenitor cells; the aggregate formed in step (2) is subjected to suspension culture in a serum-free medium or a serum-containing medium that does not contain a substance that acts on the Sonic hedgehog signal transduction pathway and a substance that acts on the BMP signal transduction pathway, but contains a substance that acts on the Wnt signal pathway, thereby obtaining an aggregate containing retinal pigment epithelium cells.

The invention discloses a compound for inhibiting proliferation of Sonic Hedgehog type myeloblastoma and promoting differentiation and application of the compound, and belongs to the technical field of biological medicine. The neuron inducer is obtained through screening, the molecular formula of the neuron inducer is C27H21ClN2O3, the CAS Number is 937807-66-4, and the compound can remarkably up-regulate mRNA and protein expression of NeuroD1 in tumor cells, promote differentiation of medulloblastoma towards neurons and inhibit malignant proliferation, so that growth and diffusion of tumors are inhibited fundamentally, the treatment effect of low toxicity and high efficiency is shown, and the neuron inducer has a good application prospect. Therefore, the compound has important development and application values in clinical treatment of the myeloblastoma, and the compound can be used for preparing the medicine for treating the myeloblastoma by trying to prepare the medicine for treating the myeloblastoma.

A cell population comprising Corin- and / or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and / or Lrtm1 positive cells are collected using a substance that binds to Corin and / or a substance that binds to Lrtm1, and dopaminergic neuron progenitor cells are produced by performing suspension culture of the Corin positive and / or Lrtm1 positive cells in a culture solution containing one or more nutritional factors:(1) a step of performing adhesion culture of pluripotent stem cells in a medium for maintaining undifferentiated state containing a Sonic hedgehog (SHH) signal stimulant, and an undifferentiated state-maintaining factor in the absence of feeder cells but in the presence of an extracellular matrix, and(2) a step of culturing the cell population obtained in the step (1) in a culture solution containing one or more differentiation-inducing factors.

Provided are compositions and methods that block the interaction between Sonic hedgehog (Shh) and Surfeit locus protein 4 (SURF4), particularly for use in treating subjects with cancer or at risk of suffering from cancer. The subject methods block the interaction between SURF4 and Shh, either by mutating residue E50, D53, D56, or any combination thereof of SURF4 or mutating the CW motif (amino acid residues 32-38) on human Shh. Also provided is a composition comprising a polypeptide that contains the CW motif at the position of 32-38 on human Shh, a polypeptide that contains the first luminal loop (residues 49-60) of human SURF4, or small chemical molecules that block the interaction between SURF4 and Shh and administering said composition to a subject, particularly in subjects with cancer or at risk of suffering from cancer.

The present disclosure relates to a method for preparing a cerebellar organoid, comprising: (A) a step of selective differentiation into hindbrain tissue, in which embryoid bodies formed from pluripotent stem cells are cultured in the presence of a hindbrain tissue induction medium including an endogenous WNT secretion inhibitor and a WNT signaling agonist; (B) a step of selective differentiation into dorsal metencephalic tissue, in which the embryoid bodies are cultured in the presence of a dorsal metencephalic tissue induction medium including a sonic hedgehog (SHh) signaling pathway inhibitor; and (C) a basal surface-apex surface polarization step of inducing basal surface-apex surface polarization, in which polarization of the embryoid bodies are induced in the presence of a basal surface-apex surface induction medium including an extracellular matrix-based hydrogel.

It is an object of the present invention to provide a method for efficiently producing extracellular vesicles containing biologically active materials such as sonic hedgehog (Shh). The present invention provides, as a solution, a method for producing extracellular vesicles, comprising obtaining extracellular vesicles secreted from cells subjected to a treatment of inactivating Rab GTPase such as Rab18, wherein the cells are preferably cells expressing Shh. In addition, the present invention provides, as a solution, an extracellular vesicle containing Shh and having a particle diameter of 800 nm or more and / or a volume of 109 nm3 or more.

1. Name of the product in this design: Running Shoes (Sonic Cat Awakening 2.1). 2. Purpose of this design: Running shoes for wearing. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The present invention aims to provide a method for efficiently producing a cell mass containing pituitary tissue from pluripotent stem cells. A method for producing a cell mass containing pituitary tissue, including the following steps (1) and (2):(1) a first step of suspension-culturing pluripotent stem cells to form a cell aggregate in the presence of a Wnt signal transduction pathway inhibiting substance,(2) a second step of suspension-culturing the aggregate obtained in the first step in the presence of a BMP signal transduction pathway activating substance and a Sonic hedgehog signal transduction pathway activating substance, thereby obtaining a cell mass comprising pituitary tissue.

Disclosed is a method of generating midbrain dopamine progenitors (mDAPs) from human pluripotent stem cells (hPSCs), comprising: (a) treating hPSCs with a Wnt agonist and a Wnt antagonist, to generate midbrain floor plate progenitors (mFPPs); (b) treating the mFPPs with Activin A and a sonic hedgehog (SHH) agonist to restrict the mFPPs to medial mFPPs; and (c) removing the SHH agonist and adding the Wnt agonist to differentiate medial mFPPs to mDAPs. Also disclosed is a plurality of midbrain dopamine progenitors (mDAPs) or midbrain dopamine neurons (mDANs) generated by the method as disclosed herein, and a pharmaceutical composition comprising the plurality of mDAPs. Further disclosed is a method of treating a neurological disease of a subject, comprising administering the plurality of mDAPs or the pharmaceutical composition as disclosed herein into a neurological disease site of the subject.